| Name | Title | Contact Details |
|---|
Marshall Medical Center is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Marshall Medical Center is based in Placerville, CA. You can find more information on Marshall Medical Center at www.marshallmedical.org
Alturas Analytics is a Moscow, ID-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
At UnitedHealthcare we`re dedicated to helping people live healthier lives and helping to make the health system work better for everyone by simplifying the health care experience, meeting consumer health needs and sustaining trusted relationships with care providers. These are extraordinary times in health care. The opportunities to help people live healthier have never been greater. Advanced data and technologies, breakthrough treatments and consumer choice are redefining what can be achieved. At UnitedHealthcare, part of the UnitedHealth Group family of businesses, we are working to create a system that is connected, aligned and more affordable for all involved; one that delivers high quality care, responsive to the needs of each person and the communities in which they live. With connections to more than 1.3 million physicians and care professionals and 6,200+ hospitals and care facilities across the globe, we can collaborate in new ways to improve patient care while providing customizable and comprehensive solutions in any market place, anywhere. Our Values Integrity: Honor commitments. Never compromise ethics. Compassion: Walk in the shoes of people we serve and those with whom we work. Relationships: Build trust through collaboration. Innovation: Invent the future, learn from the past. Performance: Demonstrate excellence in everything we do.
Natchez Regional Medical Center is a Natchez, MS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Ovid Therapeutics is a biopharmaceutical company focused exclusively on developing impactful medicines for patients and families living with rare neurological disorders. Ovid`s drug candidate, OV101, is currently in development for the treatment of symptoms of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies. Ovid has initiated the Phase 2 STARS trial of OV101 in adults with Angelman syndrome and a Phase 1 trial in adolescents with Angelman and Fragile X syndrome to identify doses suitable for younger patients.